948 United Therapeutics Corporation $UTHR Shares Acquired by Leuthold Group LLC

Leuthold Group LLC boosted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 9.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,132 shares of the biotechnology company’s stock after acquiring an additional 948 shares during the period. Leuthold Group LLC’s holdings in United Therapeutics were worth $6,032,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in UTHR. BlackRock Inc. acquired a new position in shares of United Therapeutics in the second quarter valued at $2,868,735,000. Janus Henderson Group PLC lifted its position in United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after purchasing an additional 70,829 shares during the period. Jupiter Topco LLC acquired a new stake in United Therapeutics during the second quarter worth $450,140,000. First Trust Advisors LP boosted its stake in United Therapeutics by 23.5% during the first quarter. First Trust Advisors LP now owns 270,578 shares of the biotechnology company’s stock worth $160,447,000 after buying an additional 51,555 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in United Therapeutics during the second quarter worth $159,522,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $598.67, for a total transaction of $4,968,961.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $27,043,121.24. This trade represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $564.51, for a total transaction of $5,362,845.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $183,151,317.93. This represents a 2.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 411,028 shares of company stock worth $218,802,969 in the last 90 days. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Price Performance

United Therapeutics stock opened at $582.46 on Tuesday. The business has a 50 day simple moving average of $535.33 and a 200 day simple moving average of $533.99. The company has a market capitalization of $24.98 billion, a PE ratio of 21.98, a price-to-earnings-growth ratio of 4.41 and a beta of 0.49. United Therapeutics Corporation has a one year low of $445.81 and a one year high of $614.23.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The company had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. During the same quarter last year, the company earned $7.16 earnings per share. The business’s revenue was up 4.1% on a year-over-year basis. Equities analysts anticipate that United Therapeutics Corporation will post 24.77 earnings per share for the current fiscal year.

United Therapeutics announced that its board has authorized a stock buyback program on Thursday, October 22nd that permits the company to repurchase $2 billion in outstanding shares. This buyback authorization permits the biotechnology company to buy up to 8.3% of its shares through open market purchases. Share buyback programs are often an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on UTHR. JPMorgan Chase & Co. dropped their price objective on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a research note on Wednesday, October 28th. BTIG Research raised their price objective on shares of United Therapeutics from $728.00 to $768.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. HC Wainwright began coverage on shares of United Therapeutics in a research report on Monday. They set a “buy” rating and a $660.00 target price on the stock. TD Cowen upped their target price on shares of United Therapeutics from $675.00 to $700.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Finally, Royal Bank Of Canada upped their target price on shares of United Therapeutics from $697.00 to $725.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $676.40.

United Therapeutics Profile

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma.

Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.